Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 5
2019 7
2020 11
2021 15
2022 15
2023 18
2024 21
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M; HELIOS-A Collaborators. Adams D, et al. Amyloid. 2023 Mar;30(1):1-9. doi: 10.1080/13506129.2022.2091985. Epub 2022 Jul 23. Amyloid. 2023. PMID: 35875890 Free article. Clinical Trial.
Antibody-Associated Reversal of ATTR Amyloidosis-Related Cardiomyopathy.
Fontana M, Gilbertson J, Verona G, Riefolo M, Slamova I, Leone O, Rowczenio D, Botcher N, Ioannou A, Patel RK, Razvi Y, Martinez-Naharro A, Whelan CJ, Venneri L, Duhlin A, Canetti D, Ellmerich S, Moon JC, Kellman P, Al-Shawi R, McCoy L, Simons JP, Hawkins PN, Gillmore JD. Fontana M, et al. Among authors: razvi y. N Engl J Med. 2023 Jun 8;388(23):2199-2201. doi: 10.1056/NEJMc2304584. N Engl J Med. 2023. PMID: 37285532 No abstract available.
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.
Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, Damy T, Garcia-Pavia P, Taubel J, Solomon SD, Sheikh FH, Tahara N, González-Costello J, Tsujita K, Morbach C, Pozsonyi Z, Petrie MC, Delgado D, Van der Meer P, Jabbour A, Bondue A, Kim D, Azevedo O, Hvitfeldt Poulsen S, Yilmaz A, Jankowska EA, Algalarrondo V, Slugg A, Garg PP, Boyle KL, Yureneva E, Silliman N, Yang L, Chen J, Eraly SA, Vest J, Maurer MS; HELIOS-B Trial Investigators and Collaborators. Fontana M, et al. N Engl J Med. 2025 Jan 2;392(1):33-44. doi: 10.1056/NEJMoa2409134. Epub 2024 Aug 30. N Engl J Med. 2025. PMID: 39213194 Clinical Trial.
Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis.
Rauf MU, Hawkins PN, Cappelli F, Perfetto F, Zampieri M, Argiro A, Petrie A, Law S, Porcari A, Razvi Y, Bomsztyk J, Ravichandran S, Ioannou A, Patel R, Starr N, Hutt DF, Mahmood S, Wisniowski B, Martinez-Naharro A, Venneri L, Whelan C, Roczenio D, Gilbertson J, Lachmann HJ, Wechalekar AD, Rapezzi C, Serenelli M, Massa P, Caponetti AG, Ponziani A, Accietto A, Giovannetti A, Saturi G, Sguazzotti M, Gagliardi C, Biagini E, Longhi S, Fontana M, Gillmore JD. Rauf MU, et al. Among authors: razvi y. Eur Heart J. 2023 Jun 25;44(24):2187-2198. doi: 10.1093/eurheartj/ehad139. Eur Heart J. 2023. PMID: 36946431 Free PMC article.
Conventional heart failure therapy in cardiac ATTR amyloidosis.
Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, Jiang A, Cabras G, Filisetti S, Bolhuis RE, Bandera F, Venneri L, Martinez-Naharro A, Law S, Kotecha T, Virsinskaite R, Knight DS, Emdin M, Petrie A, Lachmann H, Wechelakar A, Petrie M, Hughes A, Freemantle N, Hawkins PN, Whelan C, McMurray JJV, Gillmore JD, Fontana M. Ioannou A, et al. Among authors: razvi y. Eur Heart J. 2023 Aug 14;44(31):2893-2907. doi: 10.1093/eurheartj/ehad347. Eur Heart J. 2023. PMID: 37216684 Free PMC article.
Cardiopulmonary Exercise Testing in Evaluating Transthyretin Amyloidosis.
Patel RK, Bandera F, Venneri L, Porcari A, Razvi Y, Ioannou A, Chacko L, Martinez-Naharro A, Rauf MU, Knight D, Brown J, Petrie A, Wechalekar A, Whelan C, Lachmann H, Muthurangu V, Guazzi M, Hawkins PN, Gillmore JD, Fontana M. Patel RK, et al. Among authors: razvi y. JAMA Cardiol. 2024 Apr 1;9(4):367-376. doi: 10.1001/jamacardio.2024.0022. JAMA Cardiol. 2024. PMID: 38446436
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy.
Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, Bordignon L, Masri A, Serenelli M, Urey M, Musumeci B, Cipriani A, Canepa M, Badr-Eslam R, Kronberger C, Chimenti C, Zampieri M, Allegro V, Razvi Y, Patel R, Ioannou A, Rauf MU, Petrie A, Whelan C, Emdin M, Metra M, Merlo M, Sinagra G, Hawkins PN, Solomon SD, Gillmore JD, Fontana M. Porcari A, et al. Among authors: razvi y. J Am Coll Cardiol. 2024 Jun 18;83(24):2411-2422. doi: 10.1016/j.jacc.2024.03.429. J Am Coll Cardiol. 2024. PMID: 38866445 Free article.
Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years.
Ioannou A, Patel RK, Razvi Y, Porcari A, Sinagra G, Venneri L, Bandera F, Masi A, Williams GE, O'Beara S, Ganesananthan S, Massa P, Knight D, Martinez-Naharro A, Kotecha T, Chacko L, Brown J, Rauf MU, Manisty C, Moon J, Lachmann H, Wechelakar A, Petrie A, Whelan C, Hawkins PN, Gillmore JD, Fontana M. Ioannou A, et al. Among authors: razvi y. Circulation. 2022 Nov 29;146(22):1657-1670. doi: 10.1161/CIRCULATIONAHA.122.060852. Epub 2022 Nov 3. Circulation. 2022. PMID: 36325894 Free PMC article.
Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Porcari A, Razvi Y, Masi A, Patel R, Ioannou A, Rauf MU, Hutt DF, Rowczenio D, Gilbertson J, Martinez-Naharro A, Venneri L, Whelan C, Lachmann H, Wechalekar A, Quarta CC, Merlo M, Sinagra G, Hawkins PN, Fontana M, Gillmore JD. Porcari A, et al. Among authors: razvi y. Eur J Heart Fail. 2023 Apr;25(4):515-524. doi: 10.1002/ejhf.2776. Epub 2023 Jan 30. Eur J Heart Fail. 2023. PMID: 36644836 Free article.
75 results